ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
18.09.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1. |
---|---|
Bibliography: | Application Number: EP20220817150 |